
You are here: Home / Diseases & Conditions / New drug to treat muscle wasting disease inclusion body myositis (IBM)...

A new drug to treat the muscle wasting disease inclusion body myositis (IBM) reverses key symptoms in mice and is safe and well-tolerated in patients, finds a new study led by the Medical Research Council (MRC) Centre for Neuromuscular Diseases at University College London (UCL) and the University of Kansas Medical Center.
The study, published in Science Translational Medicine, found that the new drug Arimoclomol reversed the disease’s effects at the cellular level and improved muscle strength in mice. A safety trial in 24 IBM patients conducted in London and Kansas found that the drug was safe and well-tolerated. IBM is the most common muscle disease in people over 45.
Read full article: Medical Xpress
Recent Posts
- The American Health Council Appoints Dr. James Bashkin, D.Phil. to the Physician Board March 31, 2020
- The American Health Council Appoints Dr. Robert W. Letton, MD to the Physician Board March 19, 2020
- The American Health Council Appoints Dr. Akwasi Adjei to the Industry Board January 17, 2020
- The American Health Council Appoints Dr. Nelson Leung to the Physician Board January 17, 2020
- The American Health Council Appoints Ms. Karie Soost to the Physician Board January 17, 2020
- The American Health Council Appoints Mr. Gregory King to the Industry Board January 17, 2020